Literature DB >> 3004027

Detection and characterization of the protein encoded by the v-rel oncogene.

N R Rice, T D Copeland, S Simek, S Oroszlan, R V Gilden.   

Abstract

To identify the protein encoded by v-rel, the oncogene of reticuloendotheliosis virus (REV-T), antisera have been raised to three synthetic peptides derived from the translation of our previously published v-rel DNA sequence [R.M. Stephens, N.R. Rice, R.R. Hiebsch, H.R. Bose, Jr., and R.V. Gilden, Proc. Natl. Acad. Sci. USA 80, 6229-6233 (1983)]. Sera to all three peptides precipitate a 59,000 Da protein from REV-T-transformed chicken lymphoid cells. This protein is not detectable in uninfected chick embryo fibroblasts, and its observed size is in good agreement with the 56,000 Da predicted by the DNA sequence. We conclude that this protein is the v-rel product and designate it p59rel. To search for evidence of post-translational processing of this protein, cells were grown in the presence of glycosylation inhibitors. These resulted in no detectable difference in the size of p59rel. Nor was its size detectably altered during the course of a pulse-chase experiment. Growth of cells in the presence of [32P] orthophosphate, however, revealed that p59rel is a phosphoprotein. It is also closely associated with a protein kinase activity, for precipitation with one of the peptide antisera (but not the other two) resulted in strong kinase activity in the immune complex pellet. During this reaction, p59rel itself becomes phosphorylated. Kinase activity was retained in the immune complex following detergent and high salt washes, leaving open the possibility that p59rel is itself a kinase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3004027     DOI: 10.1016/0042-6822(86)90123-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  20 in total

1.  vRel is an inactive member of the Rel family of transcriptional activating proteins.

Authors:  P M Richardson; T D Gilmore
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

2.  Avian reticuloendotheliosis virus-transformed lymphoid cells contain multiple pp59v-rel complexes.

Authors:  N Davis; W Bargmann; M Y Lim; H Bose
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

3.  Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport.

Authors:  R L Dewar; M B Vasudevachari; V Natarajan; N P Salzman
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

4.  Transactivation of gene expression by nuclear and cytoplasmic rel proteins.

Authors:  M Hannink; H M Temin
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

5.  v-rel oncoproteins in the nucleus and in the cytoplasm transform chicken spleen cells.

Authors:  T D Gilmore; H M Temin
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

6.  The v-rel oncogene product is complexed to a 40-kDa phosphoprotein in transformed lymphoid cells.

Authors:  H Y Tung; W J Bargmann; M Y Lim; H R Bose
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

7.  Expression of the bovine leukemia virus X region in virus-infected cells.

Authors:  N R Rice; S L Simek; G C Dubois; S D Showalter; R V Gilden; R M Stephens
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

8.  The c-rel protooncogene product c-Rel but not NF-kappa B binds to the intronic region of the human interferon-gamma gene at a site related to an interferon-stimulable response element.

Authors:  A Sica; T H Tan; N Rice; M Kretzschmar; P Ghosh; H A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

9.  Moloney murine leukemia virus activates NF-kappa B.

Authors:  J Pak; D V Faller
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  p105, the NF-kappa B p50 precursor protein, is one of the cellular proteins complexed with the v-Rel oncoprotein in transformed chicken spleen cells.

Authors:  A J Capobianco; D Chang; G Mosialos; T D Gilmore
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.